CARB-X Application Round #3 goes live!

Dear All:

The wait is over — CARB-X has today released a call for new applications! The call has an interesting 2-round structure and you’ll need to study carefully both the press release and the supplemental details document to understand where your program would fit. Here’s my summary:

  • Round 1:
    • Submission window for Expressions of Interest: 22-29 March 2018
    • Scope: Restricted to new classes of direct-acting small molecule and large molecule antibacterials that have potential to cover the top 6 Gram-negative pathogen groups from the WHO and CDC priority listsA. baumannii (carbapenem-R), P. aeruginosa (carbapenem-R), Enterobacteriaceae (carbapenem-R and/or 3rd-gen ceph-R), Salmonellae spp. (fluoroquinolone-R), N. gonorrhoeae (3rd-gen ceph-R, fluoroquinolone-R), and Shigella spp. (fluoroquinolone-R).
  • Round 2:
    • Submission window for Expressions of Interest: 1-8 June 2018
    • Scope: Both direct- and indirect-acting therapeutics as well as vaccines, diagnostics and devices that meet certain criteria.
    • In terms of therapeutics, both novel and known classes are acceptable.

The very tight focus of Round #1 feels right to me … we really need to push hard at a global level on the creation of entirely novel classes of direct-acting agents. These will be rare but they are needed.

The scope of Round #2 is then broad and roughly comparable to the scope of prior CARB-X funding rounds.

With an announced portfolio of more than 20 projects and its search for both new accelerators and new staff, CARB-X continues to lead the charge against AMR. Exciting times! 

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog/

Upcoming meetings of interest to the AMR community:

Share

The road to UNGA 2024 is paved with … reports!

Dear All, We’re now well into the run-up to the HLM (High-Level Meeting) on AMR during UNGA 2024 (the UN General Assembly, September 2024, see the 15 Apr 2023 newsletter for details). In preparation, reports providing data to support policy and decision-making are continuing to appear. Today, for example, GCOA and IDSA released their report entitled “2024

Leaving the lab: The decline in AMR R&D professionals

Dear All, The AMR Industry Alliance has today released a fascinating and disturbing report. Entitled “Leaving the Lab: Tracking the Decline in AMR R&D Professionals” (press release, report itself), its key message of “Researchers Are Leaving the AMR Field – Even as the Threat Rapidly Grows” is illustrated vividly by the report’s graphics. I’m going

ADVANCE-ID seeks antibiotic for P2/3 development Asia!

Dear All, Yow! Led by David Paterson,  ADVANCE-ID (ADVANcing Clinical Evidence in Infectious Diseases) is a research group launched March 2023 as a network of more than 30 hospitals across Asia. The exciting news is that ADVANCE-ID have just announced that they are seeking a novel antimicrobial agent vs. MDR Gram-negatives that could be advanced in the clinic

Which came first: The drug or resistance to the drug?

Dear All, Although it seems entirely reasonable that the “Which came first?” chicken vs. egg riddle can be resolved in favor of the egg, a pair of papers in CID suggest that the answer to the parallel question of “drug vs. resistance to the drug” is changing in a way that is NOT in our favor!

Scroll to Top